DISA Limited Holds Extraordinary General Meeting – Shareholders Approve Strategic Expansion into Healthcare Sector

Overview

DISA Limited convened its Extraordinary General Meeting (EGM) on October 24, 2025, at its Singapore headquarters. The meeting was chaired by Mr. Chng Weng Wah, who also serves as the Executive Chairman, Managing Director, and CEO. Other board members present included Mr. Lim Soon Hock (Lead Independent Director), Mr. Low Yeow Boon (Non-Executive Independent Director), and Mr. George Kho Wee Hong (Non-Executive and Non-Independent Director).

Key Points from the EGM

• Quorum and Notice: The Company Secretary confirmed a quorum was present. The Notice of EGM dated October 9, 2025, was taken as read. Shareholders had the opportunity to submit questions in advance, but none were received prior to the meeting. Questions were permitted during the session.
• Voting Procedures: In accordance with SGX Catalist Rule 730A(2), voting on the resolution was conducted by poll. The Chairman acted as proxy for certain shareholders, voting according to their instructions. Convene SG Pte. Ltd. was appointed as polling agent and Complete Corporate Services Pte. Ltd. as scrutineer.
• Agenda – Expansion into Healthcare:
  • The sole resolution sought shareholder approval for the Group’s expansion into the healthcare sector – specifically, the establishment of integrated rheumatology medical and therapy centres.
  • This expansion is described in detail in Section 2.2 of the Circular dated October 9, 2025.
• Shareholder Concerns Addressed:
  • One shareholder raised concerns about the Group’s ability to fund the new business, citing an absence of a sustainable “cash cow.”
  • The Chairman responded by outlining plans for bank financing to support capital expenditures. He also assured that current revenues from Rheumatology Associates Pte. Ltd. are sufficient to cover operating costs for the new venture.
• Voting Results:
  • The resolution passed overwhelmingly, with 4,391,260,990 shares (100%) in favour and 3,000,000 shares (0%) against.
• Resolution Passed:
  • The Group is now authorised to expand its business into the healthcare sector, invest in, acquire, or dispose of related assets/entities, and directors have full authority to execute all necessary transactions and agreements to implement this expansion.

Price Sensitive & Investor Impact

• Strategic Shift into Healthcare: This represents a major strategic pivot for DISA Limited, transitioning from its existing business into healthcare – a sector with significant growth potential and resilience.
• Funding and Execution: The company’s assurance of sufficient operational revenue, combined with plans for bank financing, may ease concerns about financial risk. However, investors should monitor execution risks and future capital requirements.
• Potential for Share Price Movement: The entry into integrated rheumatology therapy centres could unlock new revenue streams and diversify the Group’s earnings base, making this announcement highly relevant for share valuation.
• Board Empowerment: The Board now has broad discretionary authority to pursue healthcare-related investments and transactions, which could lead to further corporate actions or acquisitions.

Conclusion

The EGM marks a turning point in DISA Limited’s corporate strategy. With overwhelming shareholder support, the Group is set to expand into the healthcare sector, targeting integrated rheumatology medical and therapy centres. This significant diversification and the authorisation for further investments and acquisitions in healthcare could have a material impact on the company’s future growth prospects, risk profile, and ultimately, its share price.

Investors should closely monitor subsequent announcements regarding the implementation, financing structure, and performance of the new healthcare business.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to transact in the securities of DISA Limited. Investors should conduct their own independent analysis and consult with professional advisors before making any investment decisions. The information herein is based on company disclosures and public announcements, and may be subject to change.

View DISA W261218 Historical chart here